Healthcare
Stereotaxis, Inc.(STXS)
Live Price
Offline$1.88
+5.62% today
1Y Change
-13.74%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $190.00M
- Revenue Growth
- +20.3%
- EPS Growth
- +16.7%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stereotaxis, Inc. (STXS) is a Healthcare stock with a market cap of $190.00M and listed on AMEX. The stock last traded around $1.88 and down 13.7% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +20.3%, EPS growth of +16.7%, a dividend yield of 0.0%. What stands out right now is revenue +20.3%, EPS +16.7%, free cash flow -61.5% with operating margin -68.3% and ROIC -72.4%. Valuation sits in the middle of the pack at price/sales 5.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STXS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.3% vs +7.6% peer median
Operating Margin
Below sector median
-68.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +20.3% and EPS at +16.7%, with operating margin around -68.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +2.1% | -5.3% | -1.6% |
2026 Mar 9, 2026 | +0.0% | -4.8% | -7.7% | -10.6% |
2025 Nov 11, 2025 | +50.0% | -14.7% | -19.6% | -16.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STXS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STXS Max Drawdown
-51.54%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STXS and SPY.
Company Overview
Stereotaxis, Inc.
New York Stock Exchange American
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
- Leadership
- David Leo Fischel
- IPO Date
- Aug 12, 2004
- Employees
- 139
- Street Address
- 710 North Tucker Boulevard
- Mailing
- Saint Louis, MO, 63101
- Region
- Saint Louis, MO, US
- Reporting Currency
- USD
- Investor Line
- 314 678 6100
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.8
- Price/Book
- 9.9
Growth
- Revenue
- +20.3%
- EPS
- +16.7%
- Free Cash Flow
- -61.5%
Profitability
- Gross Margin
- 52.7%
- Operating Margin
- -68.3%
- Net Margin
- -66.8%
- ROE
- -191.6%
- ROIC
- -72.4%
Balance Sheet
- Debt/Equity
- 0.29
- Current Ratio
- 1.51
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.